Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.

Lei YangYi ChenNing LiuQianCheng ShiXiaodong HanWeidong GanDongmei Li

Published in: Journal of hematology & oncology (2021)

TRAF3IP2-AS1 functions as a tumor suppressor in NONO-TFE3 tRCC progression and may serve as a novel target for NONO-TFE3 tRCC therapy. TRAF3IP2-AS1 expression has the potential to serve as a novel diagnostic and prognostic biomarker for NONO-TFE3 tRCC detection.

Keyphrases

poor prognosis
renal cell carcinoma
binding protein
dna damage
long non coding rna
cell proliferation
dna repair
stem cells
oxidative stress
risk assessment
pi k akt
loop mediated isothermal amplification
mesenchymal stem cells
human health
real time pcr
label free
cell therapy
smoking cessation